Inside the study for a remedy to fight Congo's deadliest Ebola outbreak
Summary
A medical trial is underway in Congo to test an experimental pill that could stop people from getting Ebola after exposure to the virus. The trial focuses on the Bundibugyo virus, responsible for the deadliest ongoing Ebola outbreak in the country, which lacks approved treatments or vaccines.Key Facts
- More than 250 people have joined the trial to test the antiviral pill obeldesivir.
- The trial started in July in the Ituri province, where the outbreak is worst.
- Participants include health workers and family members who had close contact with Ebola patients.
- The drug is given soon after exposure to prevent symptoms from developing, known as post-exposure prophylaxis (PEP).
- Over 8,300 confirmed cases and about 4,000 deaths have been reported since May.
- The trial plans to recruit nearly 1,000 people over age 12 with no Ebola symptoms but recent contact with confirmed cases.
- Half of the participants receive the pill, half receive a placebo (a dummy treatment).
- Participants are monitored daily for 21 days and by phone on day 42 to track if symptoms develop.
- If symptoms appear, patients receive immediate supportive care to improve outcomes.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
